- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01910935
Effectiveness of Physical Activity Prescription Among Hypertensive Patients of Primary Health Care.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Secondary Hypothesis:
The intervention achieved a significant change in the group of hypertensive patients in the following variables:
- Decreased levels of systolic and diastolic blood pressure, biochemical markers such as total cholesterol, triglycerides and fasting blood glucose and increased HDL cholesterol.
- Increase muscular endurance and cardio-respiratory capacity according to the categories of risk stratification.
- Decreased body weight, body mass index and waist circumference.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Morelos
-
Cuernavaca, Morelos, Mexico, 62000
- Instituto Mexicano del Seguro Social. Morelos. HGR/MF. No, UMF 3, UMF 20, UMF 23
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- diagnosed with high blood pressure <5 years of evolution and / or without use of drug therapy to treat that condition;
- with low levels of physical activity (PA) or physically inactive (less than 150 minutes of PA at week, intensity moderate to vigorous);
- with availability to PA practice or considering begin to PA practice within the next six months (contemplation or preparation stages of the Transtheoretical Model).
- Without cardiovascular risk (assessed previously);
- Without physical or mobility problems that impede PA practice;
- Willingness to participate in the study, fulfill with outlined activities to develop the proposal.
Exclusion Criteria:
- high-risk patients according to the risk stratification of the American College of Sports Medicine;
- fulfill the high recommendation of physical activity (more than 300 minutes per week of moderate to vigorous intensity);
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Physical activity prescription
24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
|
Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks.
Led by the trained staff in physical activity to patients with chronic diseases.
|
|
Ingen indgriben: No physical activity prescription
Provide information to patients about the benefits of physical activity and how to increase it safely.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Physical activity. Level of physical activity between intervention and control groups.
Tidsramme: 24 weeks
|
The length of the intervention is 24 weeks, the control group will be followed for 24 weeks also. The outcome measure is a composite at three moments of the study. Basal measurement, 24 weeks and 36 weeks, this last moment to assess sustainability of the intervention. The intervention will be effective if the difference in the percent of population (complying the minimum recommended of physical activity) among control and intervention groups is at least of 20%. |
24 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood pressure
Tidsramme: 24 weeks
|
Blood pressure among intervention and control groups, at the three moments of the study: basal measurement, 24 weeks (end of the intervention) and 36 weeks.
The outcome measure is a composite at three moments of the study.
Basal measurement, 24 weeks and 36 weeks, this last moment to assess sustainability of the intervention.
|
24 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite measure of biochemical markers: total cholesterol, triglycerides and fasting blood glucose
Tidsramme: 24 weeks
|
Biochemical markers (total cholesterol, triglycerides and fasting blood glucose) among intervention and control groups, at the three moments of the study: basal measurement, 24 weeks (end of the intervention) and 36 weeks.
The secondary outcome measure is a composite at three moments of the study.
Basal measurement, 24 weeks and 36 weeks, this last moment to assess sustainability of the intervention.
|
24 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Gallegos-Carrillo Katia, D. Sc, Instituto Mexicano del Seguro Social/Unidad de Investigación Epidemiologica y en Servicios de Salud.
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2009-785-038
- FIS/IMSS/PROT/G10/841 (Anden identifikator: FIS/IMSS)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forhøjet blodtryk
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
-
University Hospital, BrestIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Frankrig
-
Shanghai Zhongshan HospitalIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
-
Rutgers, The State University of New JerseyRekrutteringPulmonal arteriel hypertension | Pulmonal hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension af medfødt hjertesygdom | Pulmonal arteriel hypertension forbundet med skistosomiasis (lidelse) | Pulmonal arteriel og kronisk tromboembolisk pulmonal... og andre forholdForenede Stater